Combination of multiomics approach and BCR-ABL based molecular testing: A better way to monitor treatment regimen and disease progression in Chronic Myeloid Leukemia [OncoScan]
Ontology highlight
ABSTRACT: We screened TKI-treated-CML-samples in different-phases based on < or >10% copies of BCR-ABL, undetected and control-samples for generating transcriptomics-profile. Transcriptionally, three clusters were identified which showed correlation with BCR-ABL transcript-levels i.e. <10% copies (I-cluster) , undetectable (II-cluster) and >10% copies (III-cluster). CML-new cases as well as Tyrosiine kinase treated-different phases of CML
ORGANISM(S): Homo sapiens
SUBMITTER: Neetu Singh
PROVIDER: E-GEOD-77571 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA